<div id="readability-page-1">New insider activity at Vir Biotechnology ( (VIR) ) has taken place on November 18, 2025.<h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions </li><li> Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.</li></ul> EVP &amp; CFO Jason O’Byrne recently sold 6,799 shares of Vir Biotechnology stock, amounting to a total transaction value of $37,734. Recent Updates on VIR stock Vir Biotechnology’s stock has been influenced by several recent developments. The company announced promising results from its Phase 2 SOLSTICE trial for chronic hepatitis delta, showing significant efficacy and safety in reducing HDV RNA levels. This positive data, along with the early completion of enrollment in the ECLIPSE 1 Phase 3 trial, positions Vir favorably for future regulatory submissions. Additionally, the company’s strong financial position, with cash reserves extending into mid-2027, supports ongoing and future projects. Despite these advancements, Vir continues to face challenges with financial losses and high R&amp;D expenses. Analysts have adjusted their outlook based on these factors, highlighting the company’s strategic advancements in HDV and oncology programs, which are expected to drive future growth. Spark’s Take on VIR Stock According to Spark, TipRanks’ AI Analyst, VIR is a Neutral. Vir Biotechnology’s overall stock score is primarily impacted by its financial challenges, including negative profitability and cash flow issues. While there is progress in clinical programs and a strong cash position, these are offset by ongoing losses and high R&amp;D expenses. The technical analysis suggests a bearish trend, and the valuation indicates limited immediate return potential. To see Spark’s full report on VIR stock, click here. More about Vir Biotechnology YTD Price Performance: -24.48% Average Trading Volume: 1,443,743 Technical Sentiment Signal: Sell Current Market Cap: $783.3M</div>

EVP & CFO Jason O’Byrne of Vir Biotechnology sold 6,799 shares worth $37,734 on November 18, 2025. Despite positive trial results and a strong cash position, Vir faces financial losses and high R&D expenses. Analysts have a neutral outlook due to these financial challenges. The stock has a bearish technical sentiment and a -24.48% YTD performance.

Top Executive Sells Thousands of Vir Biotechnology Shares!